| Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. | |
| | |
MedLine Citation:
|
PMID: 21091713 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The world is facing an unprecedented increase in type 2 diabetes. Most disability and premature mortality experienced by people with diabetes is related to cardiovascular disease. This review summarizes recent evidence about approaches for managing cardiovascular risk in patients with type 2 diabetes. While optimal blood pressure targets in people with diabetes remain uncertain, new data have demonstrated the benefits of routine blood pressure lowering in these patients, when administered without regard to initial blood pressure level. Other recent data indicate that blood pressure lowering treatment in patients with diabetes needs to be continued for ongoing benefit. The effects of intensive blood glucose lowering have been evaluated recently in a number of large trials, and individually these have failed to provide evidence of cardioprotection over a 4-5 year period. However, longer-term follow-up data suggest that there may be a delay in any such benefits becoming apparent. The benefits of statin therapy in preventing cardiovascular events in diabetic patients have been recently confirmed in a systematic overview of relevant trials; however, effects of fibrate therapy appear more limited. The role of antiplatelet agents remains unknown, as adequately powered trials of aspirin for the primary prevention of cardiovascular events in patients with diabetes have not yet been completed. |
| | |
Authors:
|
Sophia Zoungas; Anushka Patel |
Related Documents
:
|
11603883 - Hyperglycemia associated with the use of atypical antipsychotics. 17160723 - Cardiovascular disease risk in youth with diabetes mellitus. 1245233 - Toxicology of some inorganic antihypertensive anions. |
Publication Detail:
|
Type: Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Annals of the New York Academy of Sciences Volume: 1212 ISSN: 1749-6632 ISO Abbreviation: Ann. N. Y. Acad. Sci. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-24 Completed Date: 2010-12-14 Revised Date: 2010-12-30 |
Medline Journal Info:
|
Nlm Unique ID: 7506858 Medline TA: Ann N Y Acad Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 29-40 Citation Subset: IM |
Copyright Information:
|
© 2010 New York Academy of Sciences. |
Affiliation:
|
Diabetes Research Program, Cardiovascular Division, The George Institute for International Health, University of Sydney, Missenden Road, NSW 2050, Australia. szoungas@george.org.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antihypertensive Agents
/
therapeutic use Cardiovascular Diseases / diagnosis*, epidemiology, etiology, prevention & control* Chemoprevention / methods Diabetes Mellitus, Type 2 / complications, diagnosis*, epidemiology, therapy* Humans Hypoglycemic Agents / therapeutic use Hypolipidemic Agents / therapeutic use Polypharmacy Prognosis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Hypoglycemic Agents; 0/Hypolipidemic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The test-retest reliability and responsiveness to change for the Hand Function Survey during stroke ...
Next Document: The genetics of type 2 diabetes: what have we learned from GWAS?